Project Grant R01EY036247
Award Date
7/1/24
Completion Date
6/30/28
Dollars Obligated
$1.3M
Federal Agency
National Eye Institute
Federal Grant Program
93.867
Assistance Type
Project Grant
Place of Performance
Tucson, AZ 85721, USA
Similar Awards
This $674,963 federal Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) is supporting Microbiotix, Inc., a clinical-stage biopharmaceutical company, to advance the development of filociclovir (FCV) as a treatment for adenoviral conjunctivitis and acute keratoconjunctivitis. The key objectives of this three-year project are to: 1) finalize the eye drop formulation with suitable preservatives, confirm efficacy in a rabbit model, and select an...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $637,333 to the University of Illinois to conduct comprehensive research on the role of the optineurin (OPTN) gene in mitigating the severity of herpetic eye disease caused by the herpes simplex virus (HSV-1) infection. The research aims to investigate the molecular mechanisms regulated by OPTN, particularly regarding viral degradation, immune responses, and the impact on corneal neurons and sensory...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $436,695 to The Johns Hopkins University to develop and evaluate a new eye drop-based drug delivery technology for treating neovascular age-related macular degeneration (nAMD) and other ocular diseases with neovascular complications. The key products and services to be delivered under this 4-year project include: Developing and characterizing new polymer-based gelling formulations to maximize the...
This $237,000 Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) supports research to evaluate the use of the FDA-approved sterol biosynthesis inhibitors pitavastatin and isavuconazonium for the treatment of Acanthamoeba keratitis (AK), a rare but severe eye infection caused by a free-living amoeba. The research aims to: 1) assess the mammalian cytotoxicity and anti-amoebic activities of pitavastatin and isavuconazonium alone and in...
The National Eye Institute (NEI) awarded a $366,523 Project Grant under the Vision Research federal grant program (CFDA 93.867) to The University of Iowa. The grant will fund research to develop a sustained drug delivery system for the treatment of wet age-related macular degeneration (wet AMD). The goal is to deliver a combination of two drugs - acriflavine, which prevents new blood vessel growth, and pirfenidone, an antifibrotic agent - using polyurethane nanocapsules that can be triggered...
The National Eye Institute (NEI) awarded a $257,785 Project Grant under the Vision Research program (CFDA 93.867) to The Leland Stanford Junior University. The grant supports the development of a refillable, microfabricated lens capsule-based drug delivery device for extended intraocular administration of biologics and immune-modulating peptides to treat non-infectious uveitis. The project aims to characterize the release of the biologic drug adalimumab and an immune-modulating peptide from...
This federal Project Grant award, valued at $488,639, was issued by the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) to investigate the mechanism underlying an outbreak of extensively drug-resistant Pseudomonas aeruginosa keratitis. The key objectives are to: 1) systematically test virulence factors unique to the outbreak strain to understand its enhanced pathogenesis, and 2) evaluate FDA-approved antimicrobials and combinations not currently used for ocular...
This $145,350 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research to investigate the intracellular pathway used by herpes simplex virus (HSV) during the entry process in human epithelial cells. The research aims to demonstrate that HSV utilizes a retrograde transport pathway to the Golgi apparatus prior to reaching the cell nucleus, which could inform the...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), provides $105,116 in funding to The University of North Texas Health Science Center at Fort Worth. The purpose of the project is to develop reconstituted high-density lipoprotein (rHDL) nanoparticles loaded with the neuroprotective drug macitentan for targeted delivery to retinal ganglion cells to treat glaucoma. The key objectives are to: (1) create and optimize the...
This Project Grant award from the National Eye Institute (NEI), under the Vision Research federal grant program (CFDA 93.867), provides $231,000.00 to investigate the potential impact of chronic HIV infection and/or anti-HIV drugs on the development and progression of ischemic retinopathies. The research will be conducted by Augusta University Research Institute, Inc. (doing business as Georgia Health Sciences), a non-profit research organization, over a 2-year period from February 1, 2025 to...